[WEBINAR] Driving Efficiency in Adeno-Associated Virus (AAV) Technologies

Show Image Description

As a promising class of therapeutics for gene therapies, Adeno-Associated Viruses (AAVs) are at the forefront of modern medicine. However, companies must overcome significant manufacturing hurdles to enhance process efficiency, improve product quality, and ensure cost-effectiveness. This webinar focuses on leveraging a data-rich approach to optimize the AAV upstream process, a critical step in accelerating the delivery of these medicines.

In this webinar, ‘Driving Efficiency in Adeno-Associated Virus (AAV) Technologies’, we will explore the optimization of the triple transient transfection step to produce AAV5. This work led to a remarkable greater >4-fold increase in the production of full AAV capsids, boosting the percentage of full capsids from approximately 15% to over 60%, while successfully maintaining genome titres and demonstrating reproducible performance across multiple scales, up to a 50L WAVE reactor.

In this presentation, Alexandra Bogdanovic, from APC’s bioprocess development team, delves into some of the key challenges and strategies associated with AAV production optimization including:

• An overview of the current AAV manufacturing process and its inherent challenges, such as reproducibility, scalability, and high costs.  

• How to leverage a 2-stage Design of Experiment (DoE) to systematically understand and optimize the transfection process. 

• The impact of critical factors like DNA amount, complexation time, and plasmid ratios on titre and product quality.  

• Key considerations for successful stepwise scale-up and the unexpected impact of the harvest method on process outcomes.  

View the Webinar